Content

Journal of Cancer Drug Resistance Sees Significant Increase in 2023 CiteScore to 6.6

Published on: 7 Jun 2024 Viewed: 225

We are thrilled to announce that the 2023 CiteScore for Cancer Drug Resistance (CDR) has been released by Scopus on June 5, 2024, showing an impressive rise from 5.5 to 6.6, placing the journal in Q1 in the Pharmacology (medical) discipline. This remarkable growth is a testament to the quality and impact of the research published in our journal and reflects the collaborative efforts and dedication of our entire community.

Firstly, we extend our heartfelt gratitude to our esteemed Editorial Board members. Your rigorous reviews, insightful feedback, and unwavering commitment to maintaining high standards have been pivotal in achieving this milestone. Your expertise and dedication have been instrumental in shaping the direction and reputation of CDR.

We also want to acknowledge our Young Editors, whose fresh perspectives and innovative approaches have significantly contributed to the journal's success. Your enthusiasm and hard work have played a crucial role in advancing our mission to disseminate groundbreaking research in the field of cancer drug resistance.

To our loyal readers, we owe a special thanks. Your engagement with the journal and your continued interest in the latest developments in cancer drug resistance have been essential in driving our growth. Your support encourages us to keep striving for excellence and pushing the boundaries of scientific knowledge.

Lastly, we express our deepest appreciation to the authors who have chosen CDR as the platform to publish their research. Your trust in our journal and your contributions of high-quality, impactful studies have been the cornerstone of our success. We are honored to publish your work and to share your discoveries with the global scientific community.

As we celebrate this significant achievement, we reaffirm our commitment to advancing the field of cancer drug resistance through the publication of innovative and impactful research. We look forward to continuing our journey together, and we are enthusiastic about the future prospects for CDR.

Thank you all for your continued support and contributions. Together, we are making a difference in the fight against cancer.

Editor: Louise Pan
Language Editor: Catherine Yang
Production Editor: Yan Zhang
Respectfully submitted by the Editorial Office of Cancer Drug Resistance.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/